Pharmacological vitreolysis
View Patent ↗A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
1. A method for inducing posterior vitreous detachment (PVD) in an eye, the method comprising:
(a) providing microplasmin that has been preserved in an acidic buffer;
(b) adding said microplasmin to a formulation that has a pH in a range from about 6.5 to about 8; to produce a formulated microplasmin before administering said formulated microplasmin into a posterior chamber of the eye; and
(c) administering said formulated microplasmin into a posterior chamber of the eye, thereby inducing PVD in said eye.
2. The method of claim 1 , wherein the formulation further comprises a material selected from the group consisting of tranexamic acid, hexanoic acid, lysine, serine, threonine, methionine, glutamine, alanine, glycine, isoleucine, valine, alanine, aspartic acid, polyhedric alcohol, a pharmaceutically acceptable carbohydrate, glucosamine, thiamine, niacinamide, a salt, and any combination thereof.
3. The method of claim 1 , wherein said acidic buffer comprises an acid selected from the group consisting of acetic acid, benzoic acid, carboxylic acid, citric acid, hydrochloric acid, lactic acid, malic acid and tartaric acid.
4. A method for minimizing tractional forces by the vitreous on the retina of an eye, the method comprising:
(a) providing microplasmin that has been preserved in an acidic buffer
(b) adding said microplasmin to a formulation that has a pH in a range from about 6.5 to about 8; to produce a formulated microplasmin before administering said formulated microplasmin into a posterior chamber of the eye; and
(c) administering said formulated microplasmin into a posterior chamber of the eye, thereby minimizing tractional forces on the retina of said eye.
5. The method of claim 4 , wherein the formulation further comprises a material selected from the group consisting of tranexamic acid, hexanoic acid, lysine, serine, threonine, methionine, glutamine, alanine, glycine, isoleucine, valine, alanine, aspartic acid, polyhedric alcohol, a pharmaceutically acceptable carbohydrate, glucosamine, thiamine, niacinamide, a salt, and any combination thereof.
6. The method of claim 4 , wherein said acidic buffer comprises an acid selected from the group consisting of acetic acid, benzoic acid, carboxylic acid, citric acid, hydrochloric acid, lactic acid, malic acid or tartaric acid.